© Pint of Science, 2024. All rights reserved.
Join us to celebrate National Postdoc Appreciation Week (NPAW) and the invaluable contributions of our postdoctoral research community. Whether you're a postdoc, faculty member, or student, this seminar offers a unique opportunity to learn about the fantastic research happening across the School of Biological Sciences and expand your network. Don’t miss out on this chance to show your appreciation and support for your postdoc community!
Refreshments and goody bags will be provided courtesy of Proteintech.
#NPAW2024 #CelebratePostdocs @proteintech @pintofscience
Refreshments and goody bags will be provided courtesy of Proteintech.
#NPAW2024 #CelebratePostdocs @proteintech @pintofscience
Tau-tal recall- mission Alzheimer's diagnosis
Dr Mohammad Arastoo
(Research fellow)
My research focus is on generation of Anti tau antibodies that span the entirety of the tau protein. Using these antibodies in combination allows me to look at different fragments of tau in biological fluids. The ultimate aim is to obtain a disease specific molecular signature for each stage of Alzheimer's disease
Development of a serology- based diagnostic test for Type 1 Diabetes
Rodanthi Zindrili
(Serology Test Developer, EpirogenX)
Serology-based diagnostic tests play a major role in the clinical care of patients, as they are used for the prognosis, detection and the surveillance of a specific disease, including diabetes. Despite the high prevalence of diabetes, there are still no effective tests to aid the diagnostic process, nor a screening test for high-risk populations.
It is estimated that over 422 million people worldwide suffer from diabetes. The past decade has seen an alarming rise in global diabetes incidence and its complications, in addition to an increased understanding and awareness of the diversity of discrete types of this metabolic condition. Diabetes is a metabolic condition occurring due to the dysregulation of insulin production and/or insulin response leading to disequilibrium of blood glucose. The main two main forms, are type 1 and type 2 diabetes (T1D and T2D respectively). T1D is an autoimmune condition which is attributed to the destruction of the insulin-producing β-cells residing in the Langerhans islets of the pancreas. The β-cells express surface proteins which are falsely recognized as antigenic [autoantigens: insulin (IAA), glutamic acid decarboxylase (GAD65), islet tyrosine phosphatase 2 (IA2), zinc transporter 8 (Znt8) and the islet autoantigen 69kDa (ICA69)] – leading to the activation of an immunological cascade, with autoantibody production and activation of cytotoxic T cells. The current diagnostic path only detects the autoantibodies when the destruction of β-cells is > 80%, which is translated to detrimental complications for the patient, such as diabetic ketoacidosis (DKA).
This project is harnessing the merits of AI detection (EpitoPrediktTM) of the autoantigen targets, their production, purification, expression at the EpitogenX bio-scaffold system and ELISA screening against different classes of immunoglobulins (IgM, IgA, IgG) to acquire the immunological signatures of T1D and further on the development of serology test.
Expected project outcomes:
1-Develop a rapid point-of-care diagnostic single-test system of diabetes patients (out-patient clinic, GP practice) to differentiate between diabetes subtypes in symptomatic cases that does not require sample transfer to multiple laboratories.
2- Develop an accurate laboratory based single-test system to screen and identify pre-symptomatic individuals.
It is estimated that over 422 million people worldwide suffer from diabetes. The past decade has seen an alarming rise in global diabetes incidence and its complications, in addition to an increased understanding and awareness of the diversity of discrete types of this metabolic condition. Diabetes is a metabolic condition occurring due to the dysregulation of insulin production and/or insulin response leading to disequilibrium of blood glucose. The main two main forms, are type 1 and type 2 diabetes (T1D and T2D respectively). T1D is an autoimmune condition which is attributed to the destruction of the insulin-producing β-cells residing in the Langerhans islets of the pancreas. The β-cells express surface proteins which are falsely recognized as antigenic [autoantigens: insulin (IAA), glutamic acid decarboxylase (GAD65), islet tyrosine phosphatase 2 (IA2), zinc transporter 8 (Znt8) and the islet autoantigen 69kDa (ICA69)] – leading to the activation of an immunological cascade, with autoantibody production and activation of cytotoxic T cells. The current diagnostic path only detects the autoantibodies when the destruction of β-cells is > 80%, which is translated to detrimental complications for the patient, such as diabetic ketoacidosis (DKA).
This project is harnessing the merits of AI detection (EpitoPrediktTM) of the autoantigen targets, their production, purification, expression at the EpitogenX bio-scaffold system and ELISA screening against different classes of immunoglobulins (IgM, IgA, IgG) to acquire the immunological signatures of T1D and further on the development of serology test.
Expected project outcomes:
1-Develop a rapid point-of-care diagnostic single-test system of diabetes patients (out-patient clinic, GP practice) to differentiate between diabetes subtypes in symptomatic cases that does not require sample transfer to multiple laboratories.
2- Develop an accurate laboratory based single-test system to screen and identify pre-symptomatic individuals.
Map data © OpenStreetMap contributors.